Novavax (NASDAQ:NVAX) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday.
A number of other equities analysts also recently commented on NVAX. B. Riley set a $10.00 price objective on shares of Novavax and gave the stock a “buy” rating in a research note on Thursday, January 11th. Ladenburg Thalmann Financial Services increased their price objective on shares of Novavax to $2.50 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Citigroup set a $3.00 price objective on shares of Novavax and gave the stock a “hold” rating in a research note on Tuesday. Cantor Fitzgerald restated a “hold” rating and set a $2.00 price objective on shares of Novavax in a research note on Monday, December 18th. Finally, Zacks Investment Research downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Novavax currently has a consensus rating of “Hold” and a consensus target price of $2.89.
Shares of Novavax (NASDAQ:NVAX) traded up $0.08 during midday trading on Wednesday, reaching $2.42. 18,054,400 shares of the company were exchanged, compared to its average volume of 13,388,245. The firm has a market cap of $756.36, a price-to-earnings ratio of -3.56 and a beta of 2.68. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31. Novavax has a 12-month low of $0.73 and a 12-month high of $2.60.
Several hedge funds have recently modified their holdings of NVAX. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Novavax by 49.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 29,800 shares during the period. Teacher Retirement System of Texas raised its holdings in Novavax by 349.8% in the 4th quarter. Teacher Retirement System of Texas now owns 99,952 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 77,733 shares during the period. Aperio Group LLC raised its holdings in Novavax by 121.1% in the 4th quarter. Aperio Group LLC now owns 115,323 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 63,155 shares during the period. Voya Investment Management LLC raised its holdings in Novavax by 18.6% in the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 21,639 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in Novavax in the 4th quarter valued at about $172,000. 37.53% of the stock is currently owned by institutional investors.
WARNING: “Novavax (NVAX) Lifted to Strong-Buy at BidaskClub” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/21/novavax-nvax-lifted-to-strong-buy-at-bidaskclub.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.